PE20151587A1 - Composicion farmaceutica que comprende al 3-carboxi-n-etil-n,n-dimetilpropein-1-aminio o una sal farmaceuticamente aceptable del mismo - Google Patents
Composicion farmaceutica que comprende al 3-carboxi-n-etil-n,n-dimetilpropein-1-aminio o una sal farmaceuticamente aceptable del mismoInfo
- Publication number
- PE20151587A1 PE20151587A1 PE2015000876A PE2015000876A PE20151587A1 PE 20151587 A1 PE20151587 A1 PE 20151587A1 PE 2015000876 A PE2015000876 A PE 2015000876A PE 2015000876 A PE2015000876 A PE 2015000876A PE 20151587 A1 PE20151587 A1 PE 20151587A1
- Authority
- PE
- Peru
- Prior art keywords
- carboxy
- ethyl
- aminium
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 abstract 2
- PPDPFXLNXLDRNM-WLHGVMLRSA-N (e)-but-2-enedioate;3-carboxypropyl-ethyl-dimethylazanium;hydron Chemical compound OC(=O)\C=C\C([O-])=O.CC[N+](C)(C)CCCC(O)=O PPDPFXLNXLDRNM-WLHGVMLRSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invencion se refiere a una composicion farmaceutica que comprende al compuesto 3-carboxi-N-etil-N, N-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo para el tratamiento en la prevencion y el tratamiento de aterosclerosis. Ejemplos de sales farmaceuticamente aceptables de 3-carboxi-N-etil-N, N-dimetilpropan-1-aminio son: hidrogenofumarato de 3-carboxi-N-etil-N, N-dimetilpropan-1-aminio y dihidrogenofosfato de 3-carboxi-N-etil-N, N-dimetilpropan-1-aminio
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198627 | 2012-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151587A1 true PE20151587A1 (es) | 2015-12-05 |
Family
ID=47458734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000876A PE20151587A1 (es) | 2012-12-20 | 2013-12-19 | Composicion farmaceutica que comprende al 3-carboxi-n-etil-n,n-dimetilpropein-1-aminio o una sal farmaceuticamente aceptable del mismo |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN104869988B (es) |
| AR (1) | AR094084A1 (es) |
| BR (1) | BR112015014161B1 (es) |
| CA (1) | CA2895574C (es) |
| CU (1) | CU20150067A7 (es) |
| JO (1) | JO3117B1 (es) |
| MX (1) | MX362762B (es) |
| PE (1) | PE20151587A1 (es) |
| TN (1) | TN2015000236A1 (es) |
| WO (1) | WO2014096133A1 (es) |
| ZA (1) | ZA201505093B (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1009600A2 (es) * | 2009-06-25 | 2016-03-22 | Tetra S A | |
| WO2010149654A1 (en) * | 2009-06-25 | 2010-12-29 | Grindeks, A Joint Stock Company | Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt |
| LV14345B (lv) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| US20140088125A1 (en) * | 2011-04-27 | 2014-03-27 | Jsc Grindeks | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
-
2013
- 2013-12-11 JO JOP/2013/0362A patent/JO3117B1/ar active
- 2013-12-18 AR ARP130104820A patent/AR094084A1/es unknown
- 2013-12-19 BR BR112015014161-7A patent/BR112015014161B1/pt active IP Right Grant
- 2013-12-19 WO PCT/EP2013/077291 patent/WO2014096133A1/en active Application Filing
- 2013-12-19 MX MX2015008138A patent/MX362762B/es active IP Right Grant
- 2013-12-19 CA CA2895574A patent/CA2895574C/en active Active
- 2013-12-19 PE PE2015000876A patent/PE20151587A1/es not_active Application Discontinuation
- 2013-12-19 CN CN201380066810.0A patent/CN104869988B/zh active Active
-
2015
- 2015-06-01 TN TNP2015000236A patent/TN2015000236A1/fr unknown
- 2015-06-19 CU CUP2015000067A patent/CU20150067A7/es unknown
- 2015-07-15 ZA ZA2015/05093A patent/ZA201505093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014096133A1 (en) | 2014-06-26 |
| TN2015000236A1 (en) | 2016-10-03 |
| CN104869988B (zh) | 2017-07-28 |
| CA2895574C (en) | 2019-11-26 |
| MX362762B (es) | 2019-02-06 |
| JO3117B1 (ar) | 2017-09-20 |
| CU20150067A7 (es) | 2016-01-29 |
| MX2015008138A (es) | 2016-04-25 |
| AR094084A1 (es) | 2015-07-08 |
| BR112015014161B1 (pt) | 2021-02-17 |
| CN104869988A (zh) | 2015-08-26 |
| ZA201505093B (en) | 2016-04-28 |
| BR112015014161A2 (pt) | 2017-07-11 |
| CA2895574A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151654A1 (es) | Inhibidores de cdc7 | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| PE20150092A1 (es) | Composiciones farmaceuticas que contienen fumarato de dimetilo | |
| ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
| IN2014DN09434A (es) | ||
| ECSP12011585A (es) | Compuestos y composiciones para eltratamiento de enfermedades parasitarias | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| EA201590296A1 (ru) | Дейтерированный ибрутиниб | |
| BR112014028042A2 (pt) | inibidores de nampt | |
| PE20151005A1 (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| IN2014DN10670A (es) | ||
| MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| HN2011003403A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| CO6920289A2 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib. | |
| EA201690327A1 (ru) | Терапевтические способы | |
| CU20140028A7 (es) | Compuesto de benzotiazolona | |
| PE20151424A1 (es) | Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| UY33789A (es) | Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab | |
| PE20151587A1 (es) | Composicion farmaceutica que comprende al 3-carboxi-n-etil-n,n-dimetilpropein-1-aminio o una sal farmaceuticamente aceptable del mismo | |
| BR112015014145A2 (pt) | compostos antibacterianos | |
| CL2018001236A1 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |